Helminth Parasites Alter Protection against Plasmodium Infection

Victor H. Salazar-Castañon,1 Martha Legorreta-Herrera,2 and Miriam Rodriguez-Sosa1

1 Unidad de Biomedicina, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Avenida de los Barrios No. 1, Los Reyes Iztacala, 54090 Tlalnepantla, MEX, Mexico
2 Laboratorio de Inmunología Molecular, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Batalla 5 de Mayo esquina Fuerte de Loreto, 09230 Iztapalapa, DF, Mexico

Correspondence should be addressed to Miriam Rodriguez-Sosa; rodriguezm@campus.iztacala.unam.mx

Received 6 June 2014; Accepted 6 August 2014; Published 8 September 2014

Academic Editor: Abraham Landa-Piedra

Copyright © 2014 Víctor H. Salazar-Castañon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Currently, it is estimated that approximately one-third of the almost three billion people who live on less than two US dollars per day are infected with one or more helminthic parasites. Helminthic infections are prevalent throughout tropical and subtropical regions where malaria pathogens are transmitted. Malaria is the most widespread and deadliest parasitic disease. The severity of the disease is strongly related to parasite density and the host’s immune responses. Furthermore, coinfections between both parasites occur frequently. However, little is known regarding how concomitant infection with helminths and Plasmodium affects the host’s immune response. Helminthic infections are frequently massive, chronic, and strong inducers of a Th2-type response. This implies that infection by such parasites could alter the host’s susceptibility to subsequent infections by Plasmodium. There are a number of reports on the interactions between helminths and Plasmodium; in some, the burden of Plasmodium parasites increased, but others reported a reduction in the parasite. This review focuses on explaining many of these discrepancies regarding helminth-Plasmodium coinfections in terms of the effects that helminths have on the immune system. In particular, it focuses on helminth-induced immunosuppression and the effects of cytokines controlling polarization toward the Th1 or Th2 arms of the immune response.
Before analyzing the influence of helminths infection on malaria, we must first briefly outline the immune response to *Plasmodium* infection and later outline the immune response to helminths parasites, as this is important to subsequent analyses of how malaria can be modified by the helminths.

2. *Plasmodium*

Malaria is caused by protozoan parasites belonging to the genus *Plasmodium*; it is transmitted by female *Anopheles* mosquitoes. *Plasmodium* is still one of the most successful pathogens in the world and is a major cause of morbidity and mortality in tropical countries. Five species of *Plasmodium* (i.e., *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*, and *P. knowlesi*) are responsible for all human infections [11, 12].

*Plasmodium* parasites have a complicated, multistage lifecycle involving an *Anopheles* mosquito vector and a vertebrate host. The parasite develops in two stages in its human host: in the liver (the exoerythrocytic stage) and in the blood (the intraerythrocytic stage). The most characteristic features of malaria in humans are a fever that occurs every 48 to 72 h depending on the species of *Plasmodium*, chills, headache, and gastrointestinal symptoms. In a naive, untreated individual, these can rapidly escalate into cerebral malaria (CM), anemia, severe organ failure, and death [13].

2.1. Immune Response during *Plasmodium* Infection. The immune response to *Plasmodium* is poorly understood; it depends on the parasite species and the specific stage within the host [12]. In addition, it is dichotomized into the preerythrocytic response, which is directed against the sporozoite and liver-stage parasites, and the blood stage response, which is directed against merozoites and intraerythrocytic parasites.

Although animal models do not fully replicate human malaria, they are invaluable tools for elucidating immune processes that can cause pathology and death [14]. Several mouse strains have been used to study the immune response to different combinations of *Plasmodium* species, such as *P. berghei* [15–20], *P. yoelii* [15, 21–24], *P. chabaudi* [25–30], and *P. vinckeii* [31] (Table 1). These malarial models suggest that the efficiency of parasite control requires both a humoral and a cellular immune response, most likely in cooperation, although the importance of each is not entirely clear. For example, immunity to the sporozoite depends on antibodies to surface proteins, such as CSP-2 [32, 33] and liver-stage antigen (LSA-1) [34]; these antigens induce the production of antibodies that neutralize or block the invasion of hepatocytes [35]. Once sporozoites have entered the hepatocyte, the parasite clearance in mice requires CD8⁺ T cells [36], natural killer cells (NK), and NKT and γδ T cells that produce IFN-γ to eliminate infected hepatocytes [35]. When the parasite invades red blood cells (RBC), it dramatically alters the physiological and biochemical processes of its host cell. Parasite-infected RBCs (pRBC) express parasite-encoded molecules on their surface that affects the RBCs’ mobility and trafficking within the body. The parasite biomass increases very rapidly and activates innate immune mechanisms, including NK cells and γδ T cells [13].

NK cells play an important role in restricting parasite replication. The absence of NK cells is associated with low IFN-γ serum levels and increased parasitemia in mice infected with *P. chabaudi* [37]. Likewise, the absence of IFN-γ reduces the ability of mice to control and eliminate parasites, eventually resulting in the death of the animals [38, 39]. Interestingly, macrophages (Mφ), but not IFN-γ, play a major role in the control of early peaks in lethal infections with *P. yoelii* [40]. In addition, IFN-γ produced by CD4⁺ T cells plays a pivotal role in protective immunity against non-lethal strains of *Plasmodium* [41, 42]. In contrast, the infection with *P. berghei* ANKA induces high levels of IFN-γ and TNF-α which are associated with cerebral malaria [43]. However, the peak of parasitemia in athymic mice tends to be similar to the peak in WT mice. These results suggest that extrathymic T cells are the major lymphocyte subset associated with protection against malaria [44].

In a resistant strain of mice, the presence of the parasite induces the production of proinflammatory cytokines, such as IL-1β, IL-6, TNF-α, and IFN-γ. Furthermore, IL-12 is also necessary for elimination of *P. chabaudi* AS [45], *P. berghei* XAT [20], and *P. yoelii* XNL [46].

Besides, the inflammatory cytokine MIF (macrophage migration inhibitory factor) induces pathogenesis and susceptibility on BALB/c mice infected with *P. chabaudi*, high serum levels of MIF correlated with severity of disease [47]. In addition, infection of MIF knockout mice with *P. chabaudi* increases survival [48].

CD4⁺ T cells, together with B cells, are crucial to develop efficient protection in murine experimental models [49, 50]. Whereas IFN-γ, produced by TCD4⁺, activates Mφ-mediated responses [51], the antibodies produced by B cells inhibit invasion of RBCs by the parasites [52], opsonize parasitized RBCs, block pRBC adhesion to the vascular endothelium, and neutralize parasite toxins [35]. In addition, mice rendered B cell deficient by treatment with anti-μ antibodies or B cell knockout mice (μMT) are unable to clear the erythrocytic infection of *P. chabaudi* [50, 53, 54]. Specifically, the early acute infection is controlled to some extent, giving rise to chronic relapsing parasitemia that cannot be cleared. Finally, parasitemia can be reduced by adoptive transfer of B cells [50].

Antibodies also induce pathology due to parasite antigens that are freed and adhere to healthy erythrocytes; this generates anemia or autoimmune reactions that cause damage to the kidneys and other tissues [55–58]. For example, pathogenesis of malaria nephropathy is linked to subendothelial deposits of immune complexes containing IgG and IgM [59, 60]. The antibodies involved in the elimination of the parasite mainly belong to cytophilic subclasses (IgG1 and IgG3) [50, 61]. In addition, high levels of immunoglobulin E (IgE) correlate with protection against severe malaria [62–64].

Interestingly, after the peak of parasitemia, cellular immune responses should switch from Th1- to Th2-type response in *P. chabaudi* infected mice [65], because the malaria pathogenesis is caused by inappropriate or excessive inflammatory responses to eliminate the parasite [43, 66].
### Table 1: Mouse models of malaria infection. ECM: experimental cerebral malaria, PvAS: *P. vinckei* petteri arteether sensitive, PvAR: *P. vinckei* arteether resistant, Py: *P. yoelii*, and KO: knockout.

| Species | Subspecies: clone | Mouse strain and anemia | Mouse strain and CM | Useful in research | Ref. |
|---------|-------------------|-------------------------|---------------------|--------------------|------|
| *P. berghei* ANKA | | C57BL/6: lethal CD-1: lethal C57BL/6: non-lethal BALB/c: lethal | C57BL/6: susceptible CBA: susceptible BALB/c: resistant | Used as a model of ECM; there is genetic variation in the development of ECM between inbred strains | [15–17] |
| *P. berghei* K173 | | C57BL/6: lethal | | Used to study pathogenesis; differs in some aspects of pathogenesis, indicating the influence of parasite genetic variation | [18] |
| *P. berghei* NK65 | | C57BL/6: lethal | | Is a murine noncerebral malaria strain; induces a progressive increase in parasitemia, intense hepatic inflammation, and death | [19] |
| *P. berghei* XAT | | Spontaneously cleared in immune competent mice | | Irradiation-induced attenuated variant from lethal strain *Pb* NK65; comparison of immune responses induced by these lethal and attenuated parasites lead us to elucidate the mechanisms of protective immunity and pathogenesis | [20] |
| *P. yoelii* 17 NN XL | | BALB/c: non-lethal | Most strains resistant | Used to study immune mechanisms and pathogenesis; *Py* line AI is a mild line which is restricted to reticulocytes | [15] |
| *P. yoelii* 17 XL | | BALB/c: lethal C57BL/6: lethal | Most strains susceptible | Used to identify vaccine-induced immune response | [21, 22] |
| *P. yoelii* YM | | CBA: lethal | | *Py* YM is virulent infection which multiplies in both immature and mature erythrocytes YM parasites are responsible for normocyte invasion, increased virulence compared to mild line *Py* YA parasites; lines YM and A/C differed additionally in enzyme and drug-sensitivity markers | [23] |
| *P. yoelii* YA | | CBA: non-lethal | | | [24] |
| *P. chabaudi* AS | | A/J: lethal C57BL/6: non-lethal BALB/c: non-lethal | C57BL/6 IL-10KO: susceptible | Used to study immune mechanisms and immunoregulation by cytokines, to identify susceptibility loci, and to study the immune basis of pathology | [25–28] |
| *P. chabaudi* AJ | | BALB/c: non-lethal | | Used to study experimental vaccines and immunological processes that control hyperparasitaemia | [25, 27] |
| *P. chabaudi* adami DS | | C3H: lethal C57BL/6: non-lethal BALB/c: non-lethal C3H: non-lethal | | Is fast-growing and high pathogenicity, induces more anemia, weight loss, and is less infective to mosquitoes than DK strain | [29, 30] |
| *P. chabaudi* adami DK | | | | Is slower growing and less pathogenic and more selective in its invasion of subset of RBCs than DK | [29, 30] |
| *P. vinckei vinckei* | | BALB/c: lethal AKR: lethal | | Used to study pathogenesis and for chemotherapy studies; it causes aggressive, overwhelming hyperparasitaemia | [31] |
| *P. vinckei petteri* | | AKR: lethal (PvAS) AKR: non-lethal (PvAR) | | Used for drug screening and immunological studies | [31] |
Interestingly, *Plasmodium* can modulate the response of antigen presenting cells, such as Mφ and dendritic cells (DC), which leads to suppression of the immune response [67]. In the infection with *P. yoelii* YM, the DC function is affected by the presence of TNF-α [68]. Wykes et al. suggested that damage to the activity of DCs is due to a virulence factor that is present in certain parasite strains because, when DCs were transferred from mice infected with a “nonlethal” strain to mice infected with a “lethal” parasite strain, the mice were protected [46].

The regulatory T cells are extremely important to control the inflammatory process in malaria, the number of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells (Treg) increases in mice infected with *P. yoelii* [69] or *P. berghei* [70]. In addition, mice infected with the lethal *P. yoelii* XL17 show higher levels of IL-10 and TGF-β compared to mice infected with the nonlethal strain *P. yoelii* XNL, at early time points during infection [71]. Furthermore, the suppression of T cells induces lethality in mice infected with *P. yoelii*, while neutralization of TGF-β and IL-10 decreases parasitemia and prolongs the survival of infected mice [71, 72]. Accordingly, Couper et al. reported that the main sources of IL-10 in lethal infection with *P. yoelii* are Treg cells [73]. Finally, the ablation of Treg cells from *P. yoelii*-infected DEREG-BALB/c mice significantly increases T cell activation and decreases parasitemia [74]. In addition, in mice infected with nonlethal strains of *P. yoelii*, the presence of cytokines such as IL-10 and TGF-β during the chronic phase of infection was detected [71]. Thus, these data together suggest that the outcome of malaria infection could be determined by the balance of proinflammatory and regulatory immune responses, which could inhibit pathology (Figure 1).

### 3. Helminths

Helminths are multicellular worms, some of which have adapted successfully to a parasitic lifestyle. They can be classified into three taxonomic groups: cestodes (e.g., *Taenia solium*), nematodes (e.g., *Ascaris lumbricoides*), and trematodes (e.g., *Schistosoma mansoni*). Helminths vary in their biology in terms of size, lifecycle, and the diseases they cause. However, despite this complexity, helminths usually cause asymptomatic and chronic infections [76]. Helminths are among the most widespread infectious agents in human populations, especially in developing countries; they affect more than a third of the world’s population, and more than 20 species infect humans (Table 2) [1, 77–83].

#### 3.1. Immune Response during Helminth Infections

Infection of mammals by helminth parasites typically results in a conserved series of immune events that are orchestrated and dominated by T helper cell type (Th2) events, characterized by the activation of eosinophils, basophils, and mast cells; high levels of immunoglobulin E (IgE); and the proliferation of T cells that secrete IL-4, IL-5, IL-9, and IL-13 [84, 85]. Despite this response, helminths are able to modulate and suppress the host immune response to promote their own survival and their persistence in the host for a long time, resulting in chronic infection [76, 86, 87]. These mechanisms include the ability to induce regulatory responses via regulatory T cells (Treg) which express molecules that inhibit the immune response, such as glucocorticoid-induced TNFR-related protein (GITR) and the receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) [88–91]. Treg cells also secrete suppressive cytokines, such as IL-10 and TGF-β [92].

On the other hand, B regulatory cells (Breg) also contribute to immune modulation and can release IL-10 and restrict proinflammatory responses [93]. Helminths also induce the differentiation of anti-inflammatory Mφ, called alternatively activated Mφ (AAMφ) [94, 95], as well as regulatory dendritic cells (DCreg), which are characterized by the expression of the regulatory cytokines IL-10 and TGF-β [96, 97] (Figure 2).

This anti-inflammatory or regulatory response could be potentially detrimental to the host if it interferes with the development of protection against other infections that require an inflammatory response, such as *Leishmania major* [9, 98] or *Trypanosoma cruzi* [8].

The hyporesponsive immune response induced during chronic helminth infection affects not only the response to helminth antigens but also to other antigens. Several studies have examined the effect of infections on the immune response to other unrelated antigens. In particular, it has been
Table 2: Prevalence of common helminths in the world. These are estimates of the number of people with active infections. The number of people potentially exposed or with subclinical helminthic infections is much higher.

| Helminth                        | Estimated number of infected people | Ref. |
|---------------------------------|-------------------------------------|------|
| **Nematodes**                   |                                     |      |
| Ascaris lumbricoides            | 1450 billion                         | [77] |
| Trichuris trichiura             | 1050 million                         | [77] |
| Ancylostoma duodenale           | 740 million                          | [78] |
| Trichinella spiralis            | 600 million                          |      |
| Necator americanus              | 576 million                          | [1]  |
| Brugia malayi                   | 157 million                          | [1]  |
| Wuchereria bancrofti and Brugia malayi | 120 million                        | [79] |
| Strongyloides stercoralis       | 100 million                          | [80] |
| Onchocerca volvulus             | 37 million                           | [81] |
| Loa loa                        | 13 million                           | [1]  |
| **Trematodes**                  |                                     |      |
| Schistosoma spp.                | 207 million                          | [82] |
| Fasciola hepatica               | 17 million                           |      |
| **Cestodes**                    |                                     |      |
| Taenia spp.                     | 0.4 million                          | [81] |
| Hymenolepis nana                | 75 million                           |      |
| Echinococcus spp.               | 2–3.6 million                        | [83] |

Figure 2: Helminth infections are strong inducers of a Th2-type immune response. These infections are characterized by the expansion and activation of eosinophils, basophils, and mast cells (1). Their upregulation due to high levels of immunoglobulin E (IgE) and the proliferation of T cells that secrete IL-4, IL-5, IL-9, and IL-13 are part of the host immune response against the parasite (2). However, helminth infections tend to be long-lived and largely asymptomatic because helminth infections are sustained through a parasite-induced immunomodulatory network, in particular through activation of regulatory T cells (3) and systemically elevated levels of IL-10 produced by B regulatory cells (4). They are additionally affected by the expression of the regulatory cytokines IL-10 and TGF-β, produced by regulatory dendritic cells (5) and alternatively activated Mφ (AAMφ) (6).
shown that the response to vaccines can be modified by the presence of concomitant helminth infection. For example, chronic *Onchocerca* infection [99], *Lymphatic filariasis* [42], or *Schistosoma* [100] reduces the effectiveness of the tetanus vaccine. Likewise, chronic *Onchocerca* infection affects *Bacillus Calmette-Guérin* and Rubella vaccinations [101]. Similarly, *Ascaris lumbricoides* reduces the response to the oral cholera vaccine, which can be restored by albendazole treatment [102]. However, helminthic infections are beneficial in the control of excessive inflammatory reactions, such as Crohn’s disease [103] and ulcerative colitis [104], as well as in allergic diseases [105–107] and autoimmune diseases, such as encephalomyelitis [108, 109] and arthritis [110].

Despite the widespread acceptance that helminthic infections influence each other directly or indirectly, little attention has been paid to helminth- *Plasmodium* coinfections. One reason is that the interactions involved are complex and difficult to understand. Here, we will try to discuss several reports about helminth-malaria coinfections to clarify the consequences of this interaction.

4. Human *Plasmodium*-Helminth Coinfection

*Plasmodium* spp. infect between 349 and 552 million people and kill over one million each year; approximately 40% of the world’s population is at risk of being infected [2, 111]. Importantly, people living in malaria-endemic regions are exposed to other pathogens, especially those associated with poverty, such as helminths.

Several studies have been carried out to explore the influence of helminths on *Plasmodium* infection in humans (Table 3). However, the evidences described in these researches are controversial. While some studies have reported that helminth infection favors protection because reduces the *Plasmodium* parasite density [112], promotes protection against clinical malaria [113, 114], reduces anemia [113, 115, 116], cerebral malaria [117] and renal failure [118] (Table 3(a)). Other studies showed no influence of helminths on the course of *Plasmodium* infection [119–121] (Table 3(b)). In contrast, others showed an increased susceptibility to *Plasmodium* infection [114, 122], increased risk of complications [123–125], anemia [125, 126], hepatosplenomegaly [127, 128], and increased *Plasmodium* parasite load [129, 130] (Table 3(c)).

Although a Th2 phenotype is a conserved response to helminth infection in human and mice, the nature of the host immune response varies considerably between species of helminths; in some cases Th1 immune response predominates, depending on both the time of infection and the helminth development stage [131, 132]. The time that Th1 immune response is sustained until it polarizes toward Th2, could vary between species [133–135]. Thus, the controversial results related to helminth- *Plasmodium* coinfection in humans could be explained because many studies did not consider critical features of the helminth parasite biology. For example, the biological niche or parasite stage within the host. Neither the previous time of infection with the helminth nor the nutrition state and age of the host were taken into account.

Because all of these variables were not considered in existing studies in humans and in order to establish a possible consensus, we review in detail the murine *Plasmodium*-helminth coinfections, which in theory, controlled variables more rigorously.

5. Experimental Models of Coinfection

Although helminth infections in mice are a questionable model for chronic helminth infections in humans, the fact is that many intraintestinal helminths can reach large biomass which can change the cytokine environment and therefore the possible mechanisms of response. By establishing chronic infections and inducing strong Th2-type responses, helminths could have a potentially significant influence on the nature of the immune response in infected individuals and hence modify their susceptibility to subsequent infections with other important pathogens, at least those that require a Th1-type or mixed Th1-/Th2-type immune response, such as *Plasmodium* sp.

5.1. *Schistosoma*- *Plasmodium* Coinfection. According to the theory that Th2-type response evoked in response to helminth infection would have the ability to suppress proinflammatory Th1 response that generates immunopathology in *Plasmodium*-infected individuals, there are some reports of experimental models of coinfection with *Plasmodium berghei* ANKA (*Pb*) after *Schistosoma mansoni* (Sm) infection in ICR mice or with *Schistosoma japonicum*- (Sj) *Pb* in C57BL/6 mice 7 or 8 weeks after helminthic infection, respectively, both coinfections showed a delay in death of mice [136, 137]. Interestingly, there was a reduction in the brain pathology associated with high levels of the anti-inflammatory cytokines IL-5, IL-10, and IL-13 [136–138].

In contrast, similar coinfection with *Pb* 7 or 8 weeks after *Sm* infection showed an increase in mortality and parasitemia in Swiss albino and C57BL/6 mice [138, 139]. Moreover, the coinfections in Swiss albino mice reduced the effectiveness of antimalarial treatments and delayed elimination of the parasite [139] (Table 4(a)). In these reports neither evidence of immune response nor pathology data were shown. Thus, we speculate that increase parasite load was probably due to the presence of helminth than inhibited Th1-type immune response which was able to contain the replication of *Plasmodium*, and the increased mortality was due to parasite load rather than a pathological Th1-state dependent. In line with this hypothesis, coinfection with *Plasmodium chabaudi* (Pc) at 8 weeks after *Sm* infection in C57BL/6 mice allowed high *Pc* replication. This increase was associated with low levels of the proinflammatory TNF-α [140].

It is known that the immune response against *Schistosoma* shifts from an early helminth-protective Th1-type immune response to a late helminth-permissive Th2-type response during the course of infection [134]. Thus, the moment when the second infection is acquired (2, 4 and 6 weeks post-helminth infection) would be critical for disease outcome and pathology [141]. These findings could be supported by the fact that chronically *Sm*-infected BALB/c mice coinfectcd (6 weeks) with the nonlethal strain *Plasmodium yoelii* NXL.
| Study area | Age of group | Sample (size) | Study design | Helminth type | Outcome for malaria diseases in coinfection |
|------------|--------------|---------------|--------------|---------------|---------------------------------------------|
| Senegal (Niakhar) | Children | 178 | Over a 2-year followup period | S. haematobium | Children with a light S. haematobium infection presented lower P. falciparum parasite densities than children not infected by S. haematobium |
| Mali (Tieneguebougou and Bougoudiana) | Children and young adults | 62 | Followed prospectively through a malaria transmission season | Wuchereria bancrofti, Mansonella perstans | Pre-existent filarial infection attenuates immune responses associated with severe malaria and protects against anemia, but has little effect on susceptibility to or severity of acute malaria infection |
| Southern Ethiopia | 1 to 82 years Mean 18.6 years | 1,065 febrile patients | Cross-sectional | A. lumbricoides, T. trichiura, S. mansoni, and hookworm | The chance of developing non-severe malaria were 2.6–3.3 times higher in individuals infected with helminth compared to intestinal helminth-free individuals |
| South-central Côte d’Ivoire | Infants (6–23 months), children (6–8 year), and young women (15–25 years) | 732 subjects | Cross-sectional survey | Soil-transmitted helminth | Coinfected children had lower odds of anemia and iron deficiency |
| Brasil (Careiro) | School children 5 to 14 years | 236 | Cohort and cross-sectional | A. lumbricoides hookworm and T. trichiura | Interaction between P. falciparum and light-intensity hookworm infections vary with age |
| Thailand (Bangkok) | Mean 24 years (range 15–62) | 537 files | Retrospective case-control | A. lumbricoides | Helminthes protect against hemoglobin decrease during an acute malarial attack by Plasmodium |
| Thailand (Bangkok) | 19–37 years 22 patients with malaria-associated ARF and 157 patients with MSM | 179 | Retrospective case-control | A. lumbricoides, T. trichiura, hookworm, and Strongyloides stercoralis | Percentage protection for mild controls against cerebral malaria ranged from 40% for Ascaris (present/absent) to 70% for Ascaris medium infection. For intermediate controls protection against cerebral malaria was 75% for Ascaris (present/absent). |
| Study area | Age of group | Sample (size) | Study design | Helminth type | Outcome for malaria diseases in coinfection |
|------------|--------------|---------------|--------------|---------------|---------------------------------------------|
| Kenya (Kingwede) | 8 years and older | 561 | cross-sectional | S. haematobium | Children had 9.3 times the odds of coinfection compared to adults |
| Nigeria (Osun) | preschool children (6–59 months) | 690 | Double-blind and randomized | A. lumbricoides | There was no significant difference in the severity of anaemia. |
(b) Continued.

| Study area          | Age of group       | Sample (size) | Study design          | Helminth type                              | Outcome for malaria diseases in coinfection                                           | Ref. |
|---------------------|--------------------|---------------|-----------------------|--------------------------------------------|----------------------------------------------------------------------------------------|------|
| Kabale, Uganda      | All ages (856)     | 856           | Retrospective; 18 months | *A. lumbricoides, T. trichiura, and hookworm* | Non evidence for an association and risk of malaria                                      | [121]|
| Senegal (Niakhar and Bambey) | Children, mean 6.6 years | 105           | Prospective case-control | *A. lumbricoides*                           | Prevalence of *A. lumbricoides* infection was higher in cases of severe malaria         | [123]|
| Senegal             | Children aged 6–15 years | 512           | Cohort                 | *S. mansoni*                               | The incidence rate of malaria attacks was higher among *S. mansoni*-infected individuals carrying the highest worm loads. In contrast, the rate of malaria attacks were lower in medium grade *S. mansoni* infections | [124]|
| Ghana (Kumasi)      | Women (15–48 years) mean 26.8 years Children <5 years, children 5–14 years, and adults ≥15 years | 746           | Cross-sectional        | *A. lumbricoides, T. trichiura, S. stercoralis, and E. vermicularis* | Coinfection resulted in increased risks of anemia, low birth weight, and small for gestational age infants | [125]|
| Ethiopia (Alaba Kulito) | Children, <5 years, children 5–14 years, and adults ≥15 years Primary school children 4–17 years and adults ≥15 years | 1802 acute febrile patients | case-control | *Hookworm, A. lumbricoides, and T. trichiura* | Coinfection is associated with higher anaemia prevalence and low weight status than single infection with *Plasmodium* in children | [126]|
| Kenya (Makueni)     | Primary school children 4–17 years | (221 and 228) | Cross-sectional        | *S. mansoni*                               | Hepatosplenomegaly due to proinflammatory mechanism exacerbated by schistosomiasis     | [127]|
| Kenya (Mangalet)    | Children 4–17 years | 79            | Cross-sectional        | *S. mansoni*                               | Hepatosplenomegaly is associated with low regulatory and Th2 response to *Schistosoma* antigens | [128]|
| Zimbabwe (Burma Valley) | Children 6–17 years | 605           | 12-month followup of a cohort of children | Schistosome                                | Increased prevalence of malaria parasites and had higher sexual stage malaria parasite in children coinfected with schistosomiasis | [129]|
| Cameroon (Bolifamba) | 9 months to 14 years | 425 children  |                        | *A. lumbricoides, T. trichiura, and hookworm* | Coinfections in which heavy helminth loads showed high *P. falciparum* parasite loads compared with coinfections involving light helminth burden | [130]|

(c)
Table 4: Helminthic infection drives immune response to challenge with *Plasmodium*. *The time after helminth infection when the *Plasmodium* challenge was performed. ND: nondetermined, wks: weeks, KO: knockout, ECM: experimental cerebral malaria.

(a)

| Background mouse | *Plasmodium* strain | Helminth type | Coinfection time | Malaria disease outcome | Ref. |
|------------------|---------------------|---------------|------------------|-------------------------|------|
| ICR HSD          | *P. berghei* ANKA   | *S. mansoni*  | 7 wks            | Low rates of ECM (30%), delay in death associated with high levels of IL-4, IL-10 | [136] |
| C57BL/6          | *P. berghei* ANKA   | *S. japonicum*| 8 wks            | Increased survival rate and reduction of the brain pathology. Th2 response induced by worm plays an important role in protecting against ECM | [137] |
|                  | *P. berghei* ANKA   | *S. mansoni*  | 8-9 wks          | Increased parasitemia, mortality, weight loss, and hypothermia; decreased pathology in the brain associated with high levels of IL-5, IL-13 and low serum IFN-γ | [138] |
| Swiss albino     | *P. berghei* ANKA   | *S. mansoni*  | 7 wks            | Increased parasitemia and mortality | [139] |
| C57BL/6          | *P. chabaudi*       | *S. mansoni*  | 8 wks            | Increased parasitemia associated with a deficiency in the production of TNF-α | [140] |
|                  | *P. chabaudi* AS    | *S. mansoni*  | 2wks, 4, and 6 wks | Increased parasitemia and death at 6 wks of coinfection. | [141] |
|                  | *P. yoelii* NXL (non-lethal) | *S. mansoni* | 2, 4, and 6 wks | Hepatosplenomegaly was more marked in coinfectected mice compared to either disease separately | |
| A/J              | *P. chabaudi*       | *S. mansoni*  | 8 wks            | Mice escape death and showed high production of IFN-γ | [142] |

(b)

| Background mouse | *Plasmodium* strain | Helminth type | Coinfection time | Malaria disease outcome | Ref. |
|------------------|---------------------|---------------|------------------|-------------------------|------|
| C57BL/6          | *P. chabaudi* AS    | *H. polygyrus*| 2, 3, or 5 wks   | Increased parasitemia and mortality associated with low levels of IFN-γ and high levels of TGF-β, IL-10 | [143] |
|                  | *P. chabaudi* AS    | *H. polygyrus*| 2 wks            | Increased parasitemia; however, it ameliorates severe hypoxemia and hypoglycaemia; besides this, it induced earlier reticulocytosis than *Pc*-infected WT mice | [144] |
|                  | *P. chabaudi* AS    | *H. polygyrus*| At the same time | Increased mortality and severe liver disease, associated with increased IFN-γ, IL-17, and IL-22 in the liver. The coinfectected IFN−/− and IL-23−/− mice survive | [145] |
| C57BL/6          | *P. chabaudi* AS    | *H. polygyrus*| 2 wks            | Suppresses the protective efficacy of the malaria vaccine. Deworming treatment before antimalarial immunization restored the protective immunity to malaria challenge | [146] |
| BALB/c           | *P. chabaudi* AS    | *H. polygyrus*| 2 wks with AgPc + adjuvant | Increased pathology due to reduced response against *Py* (low levels of IFN-γ) in the spleen cells, as a result of higher activation of Treg | [147] |
|                  | *P. yoelii* 17 XNL  | *H. polygyrus*| 2 wks            | Reduction of pathology, low levels of IFN-γ, and high levels of IL-4 induced by helminthes | [148] |
|                  | *P. berghei* ANKA   | *H. polygyrus*| 2 wks            | *Hp* infection did not alter ECM development, despite accelerated *P. berghei* growth in vivo | [149] |
(b) Continued.

| Background mouse | Plasmodium strain | Helminth type | Coinfection time | Malaria disease outcome | Ref. |
|------------------|-------------------|---------------|------------------|-------------------------|------|
| C57BL/6 BALB/c   | *P. berghei* ANKA | *H. polygyrus* | 2 wks            | No differences          | [150]|
| (c)              |                   |               |                  |                         |      |
|                  | *C57BL/6*         | *P. yoelii*   |                  |                         |      |
|                  |                   | *17NXL*       | 3 wks            | *E. caproni*            |       |
|                  |                   | Strongyloides|                  |                         | [148]|
|                  | BALB/c            | *P. yoelii*   |                  |                         | [151]|
|                  |                   | *17NXL*       | 5 wks            |                         |       |
|                  |                   | Strongyloides|                  |                         |       |
|                  | BALB/c            | *P. berghei*  |                  |                         | [151]|
|                  |                   | *ANKA*        | 5 wks            |                         |       |
|                  | (d)               |               |                  |                         |      |
|                  | *C57BL/6*         | *P. yoelii*   |                  |                         | [152]|
|                  |                   | *17NXL*       | 1 wk             | Did not alter cytokine  |       |
|                  | Strongyloides     | *ratti*       |                  | response               | [153]|
|                  | BALB/c            | *P. berghei*  |                  |                         |       |
|                  |                   | ANKA          | 1 wk             | The coinfection did not|       |
|                  | Strongyloides     | *ratti*       |                  | change the efficacy of |       |
|                  |                   |               |                  | vaccination against     |       |
|                  |                   |               |                  | *Pb*                   |       |
| (e)              | *C57BL/6*         | *P. chabaudi* | Same day         | Reduction of anemia    | [154]|
|                  |                   |               |                  | and parasitemia. Th2    |       |
|                  |                  | Nippostrongylus|                  | response was inhibited  |       |
|                  |                  | *brasiliensis*|                  | by *Plasmodium*         |       |
|                  | BALB/c            | *P. chabaudi* | 3 wks            | Delayed peak parasitemia, | [155]|
|                  | Strongyloides     | *ratti*       |                  | increased survival      |       |
|                  |                   | *brasiliensis*|                  |                         |       |
| (f)              | *BALB/c*          | *P. chabaudi* | 8 wks            | Increased severity of   | [156]|
|                  | Strongyloides     | *ratti*       |                  | the anemia and weight   |       |
|                  |                   | *brasiliensis*|                  | loss associated with    |       |
|                  | C57BL/6 IL-10KO   | *P. berghei*  | 8 wks            | increased **IFN-γ**     | [157]|
|                  | Strongyloides     | *ratti*       |                  | Reduction of ECM        |       |
|                  |                   | *brasiliensis*|                  | associated with increased|       |
|                  | BALB/c            | *P. berghei*  | 2 wks            | IL-10                     | [153]|
|                  | Strongyloides     | *ratti*       |                  | Reduced protection      |       |
|                  |                   | *brasiliensis*|                  | against *P. berghei*    |       |
|                  | (g)               |               |                  | challenge infection for  |       |
|                  |                   |               |                  | low frequencies of CSP-     |       |
|                  |                   |               |                  | specific CD8 T cells,    |       |
|                  |                   |               |                  | CSP-specific IFN-γ and  |       |
|                  |                   |               |                  | TNF-α production        |       |
|                  | *CBA*             | *P. berghei*  |                  | Increased survival and   | [158]|
|                  | Strongyloides     | *ratti*       | 1 wk             | protected them against  |       |
|                  |                  | *brasiliensis*|                  | the ECM development;    |       |
|                  |                  |               |                  | increased synthesis of   |       |
|                  |                  |               |                  | IFN-γ, IL-4, IL-5, and  |       |
|                  |                  |               |                  | IgE                     |       |
| (h)              | *C57BL/6*         | *P. berghei*  | 1-4 wks           | Partially subdued parasitaemia and prolonged survival | [159]|
|                  | Trichinella       | *spiralis*    |                  |                         |       |
|                  |                   |              |                  |                         |       |
(PyNXL) showed high mortality. In contrast, no mortality was observed in acutely (2 or 4 weeks) coinfected mice, although they developed high parasitemia and hepatomegaly was higher in coinfected mice compared with mice infected with each parasite separately [141] (Table 3(a)). Therefore, the time of previous infection may influence the response against *Plasmodium*.

Together, these reports suggested that the Th2 response, induced by *Schistosoma*, plays an important role in protecting against immunopathology in cerebral malaria. However, the presence of *Schistosoma* does not appear to modify the virulence of *Pb* and, consequently, it does not alter the lethality of *Plasmodium* infection.

Finally, one report escape to the theory that Th2-type immune response evoked by the helminth infection would possess the ability to suppress the proinflammatory Th1-type response in its host. *Sm*-infected A/J mice coinfected at 8 weeks with *Pc* were protected by the presence of concomitant *Sm* infection. The mice escaped death due to malaria; this effect was accompanied by enhanced levels of IFN-γ [142] (Table 4(a)).

### 5.2. *Heligmosomoides polygyrus*-Plasmodium Coinfection.

Several studies used mice of the same genetic background. Additionally, equivalent helminth and *Plasmodium* strains have been used to explain whether previous helminthic infection plays an important role in the immune response against *Plasmodium*. Su et al. showed that C57BL/6 mice previously infected with *Heligmosomoides polygyrus* (*Hp*) and challenged with *Pc* either 3 or 5 weeks after helminthic infections developed high *Pc*-parasitemia and mortality, which was associated with low levels of IFN-γ and high levels of TGF-β and IL-10 [143]. However, *Hp-Pc* coinfection at 2 weeks resulted in less severe pathology (i.e., less hypothermia and hypoglycemia) and induced earlier reticulocytosis compared with mice infected only with *Pc* [144] (Table 4(b)).

**Helminby** in 2009 showed that mice developed high mortality in the *Hp-Pc* model when the two infections were introduced simultaneously. The mortality was due to severe liver pathology associated with increased IFN-γ, IL-17, and IL-22. Interestingly, when using an IFN-γ and IL-23 knockout strain, the mice survived the coinfection [145]. Thus, simultaneous *Hp-Pc* coinfection increased mortality, which may be a consequence of a synergistic effect that increased the inflammatory response (Table 4(b)).

In fact, in the first case, in which *Hp-Pc* coinfection was performed at 3 or 5 weeks after the initial helminthic infection, the high mortality observed may have been due to the anti-inflammatory response generated by the previous helminthic infection, which inhibited the inflammatory response necessary for control of the *Plasmodium* infection. However, when the coinfection was performed at the same time, mice developed a stronger inflammatory response, which generated greater pathology and mortality. This susceptibility is supported by the observation that chronic helminthic infection suppresses effective vaccine-induced protection against *Plasmodium*. However, when mice were administered with antihelminthic *Hp* treatment before malaria vaccination, the protective immunity against *Pc* was restored [146]. Therefore, the timing of the infection with *Hp* plays an important role in the type of immune response that is generated within the host, and it determines the susceptibility following challenge with *Plasmodium*.

The genetic background of mice infected with helminths has a crucial role in the outcome of the immune response to *Plasmodium*. For example, coinfection with the nonlethal *PyNXL* strain at 2 weeks after *Hp* infection in C57BL/6 mice resulted in exacerbated pathology and poor survival of mice. This susceptibility was associated with a reduced response against *PyNXL* (i.e., low levels of IFN-γ) in the spleen cells. As a consequence, it increased the activation of Treg cells [147]. However, the same coinfection at 3 weeks in BALB/c mice decreased the pathology associated with low levels of IFN-γ and increased levels of IL-4, but not IL-10 [148]. Therefore, the genetic background of mice infected with the helminth determines the outcome of *PyNXL* infection (Table 4(b)).

What happens when a lethal strain of *Plasmodium* was used in coinfection with *Hp*? The *Pb ANKA* infection in C57BL/6 mice induced typical symptoms of ECM [160, 161]. Coinfection with *Hp-Pb ANKA* 2 weeks after initial helminthic infection did not modify the development of ECM despite accelerated *Pb* growth in vivo [149]. Likewise, other results from the same model of coinfection in BALB/c and C57BL/6 mice showed no differences in parasitemia, anemia, or body weight in relation to mice infected only with *Plasmodium* [150]. Therefore, *Hp* infection does not affect the outcome of *Pb ANKA* (Table 4(b)).

### 5.3. *Echinostoma caproni*-Plasmodium Coinfection.

Studies in BALB/c mice infected for 3 weeks with *E. caproni* (*Ec*) and then coinfected with the nonlethal strain *PyNXL* showed that exacerbation of *Plasmodium*-induced pathology was associated with a deficit in IFN-γ production [148]. Similarly, when *Ec*-infected mice were coinfected at 5 weeks, increased mortality was observed. The exacerbated pathology was reversible through the clearance of *Ec* worms via praziquantel treatment [151]. However, coinfection at 5 weeks with the lethal *PyXL* strain did not alter the course of infection; all mice infected with *PyXL* (i.e., alone, in combination with *E. caproni*, or praziquantel treated) died on day 10 after infection [151] (Table 4(c)). Therefore, *Ec* infection does not affect the outcome of lethal *PyXL*, but *Ec* infection affects the protective response against a nonlethal *Plasmodium* strain.

### 5.4. *Strongyloides ratti*-Plasmodium Coinfection.

Murine *Strongyloides ratti* (*Sr*) infection is a transient helminthic infection that is resolved spontaneously within 3–4 weeks. This infection induces a strong Th2-type immune response at day 6 after infection [135]. When BALB/c mice were coinfected with the nonlethal strain *PyNXL* at day 6 after *Sr* infection, *Sr* induced a slightly enhanced peak of *Plasmodium* parasitemia and loss of body weight. In contrast, in C57BL/6 mice coinfected at day 6, parasitemia level and body weight were not altered. Interestingly, the Th2-type immune response induced by *Sr* was significantly reduced upon *PyNXL* coinfection [152]. In addition, *PyNXL* clearance was not affected by previous infection with *Sr* in either C57BL/6 or BALB/c mice. Moreover, infection with *Sr* in BALB/c...
mice did not change the efficacy of vaccination against *Pb* ANKA [153]. Therefore, infection with *Sr* does not affect the protective response against *Plasmodium*, although it generates small changes in parasitemia levels; which is not decisive for the outcome of *Plasmodium* infection (Table 4(d)).

5.5. *Nippostrongylus brasiliensis*-Plasmodium Coinfection. BALB/c mice infected with *Nippostrongylus brasiliensis* (*Nb*) exhibit a strong Th2-type immune response [162]. Even so, when BALB/c mice were coinfected with *Nb* and *Pc* simultaneously, the Th2 response against *Nb* was impaired by *Plasmodium*. Interestingly, the *Nb*-*Pc* coinfection had a beneficial effect; it slightly ameliorated the severity of malarial anemia (SMA) and decreased parasitemia levels [154]. Similarly, C57BL/6 mice infected for 3 weeks with *Nb* and then coinfected with *Pb* showed a delayed peak parasitemia and an increased survival time [155]. Thus, the presence of concomitant *Nb* infection plays an important role in inhibiting pathology associated with a challenge with *Pc* or *Pb* (Table 4(e)).

5.6. Coinfection with Other Helminths. Experimental models of coinfection with *Litomosoides sigmodontis* (*Ls*) 8 weeks and *Pc* infection in BALB/c mice showed increased SMA and weight loss associated with increased levels of IFN-γ [156]. In contrast, coinfection with *Ls* 8 weeks and *Pb* infection in C57BL/6 mice showed significantly reduced ECM rates associated with increased levels of IL-10. This protection was inhibited in IL-10 KO mice [157]. High levels of IL-10 were important in reducing pathology but also interfered with the protective response to *Plasmodium* in the liver. In particular, chronic infection with *Ls* interfered with the protective efficacy of a vaccine against sporozoite *Pb* in the liver [153]. Therefore, infection with *Ls* exacerbates the pathology of a *Pc* infection. In contrast, infection with *Ls* inhibits pathology in *Pb* infection due to an anti-inflammatory cytokine response (Table 4(f)).

In addition, CBA/J mice infected with *Brugia pahangi* (*Bp*) for 1 week and then coinfected with *Pb* displayed a low mortality rate, and mice were protected against the development of ECM. This protection was associated with increased serum IgE levels and Th2 cytokine production [158] (Table 4(g)). Similarly, infection with *Trichinella spiralis* (*Ts*) for 1 or 4 weeks in C57BL/6 mice greatly enhanced their resistance against the fatal coinfection with *Pb* [159]. Therefore, these observations suggest that the Th2-type immune response reduces brain pathology and increases survival in *Bp*- or *Ts*-*Pb* coinfection, perhaps due to the anti-inflammatory environment generated by the previous helminth infection (Table 4(h)).

The studies described above lead to different conclusions, while some of them suggest that prior infection with helminths induces resistance to *Plasmodium* [136, 137, 142, 148, 154, 155, 157–159], other studies do not show effects [149–153] and finally some others demonstrated an increased susceptibility to *Plasmodium* infection [138–141, 143–148, 151, 153, 156]. These contrasting results may partially be explained because this interaction is affected by the timing between the hosts’ exposure to the helminth and *Plasmodium*. In addition, the strain of each parasite is also important, coinfection with nonlethal *Plasmodium* strains in the early stages of a helminthic infection delayed the onset of parasitemia due to early, specific high production of IFN-γ, but this response increased pathology. In contrast, a significant increase in susceptibility to nonlethal *Plasmodium* was observed when mice were coinfected with *Plasmodium* in the late stages of helminthic infection, when the Th2-type immune response is predominant.

Coinfection with lethal strains of *Plasmodium* in the late stages of a helminthic infection inhibits severe pathology and increases the survival of mice due to a decrease inflammatory response (mainly IFN-γ and TNF-α). In addition, the presence of a late anti-inflammatory Th2-type immune response induced by helminthic infection extended the survival of mice susceptible to *Plasmodium* infection; this may be due to a reduced pathological Th1-type immune response or may be due to induction of protective mix of Th1 and Th2 immune response. Recruitment and activation of Mφ by helminth infections may modulate the excessive inflammatory Th1-type immune response. The expansion of Treg cells and the alternative activation of Mφ by helminth infections may modulate the excessive inflammatory response to *Plasmodium*. Therefore, the chronic helminth infections inhibited pathology and increased survival in the challenge with lethal strains of *Plasmodium*.

6. Conclusions

The findings in this review demonstrate that the immune environment generated by a previous helminthic infection influences the response against *Plasmodium*. A helminth that persists in its host is able to significantly modify the host’s susceptibility to or protection from *Plasmodium*. These modifications are dependent on the genetic background of mice, the type of helminth, and the time-course of the initial helminthic infection, which is crucial to the resulting immune response to *Plasmodium*.

The impact of helminth-*Plasmodium* coinfection on acute helminthic infection increased or synergized the Th1-type immune response. This might be successful in inducing a response that inhibits *Plasmodium* replication, but it increases the pathology and mortality in the host. Alternatively, chronically helminth-infected mice showed a shift toward Th2-type immune responses. This could render the host more susceptible to *Plasmodium* infection and favor their replication; however, this response protected the host from severe malaria (Figure 3). Overall, these results suggest that malarial immunity is influenced by helminth infections. Therefore, the study and manipulation of antimalarial immunity seems difficult in the absence of any information concerning the effects of helminths on this response.

7. Perspectives

The helminth-*Plasmodium* interaction may have undesirable implications for global public health; for example, malaria
vaccines trials do not consider the immune response to helminths, and this could result in decreased performance or cause adverse effects. Thus, a better understanding of helminth-induced regulation in the antimalarial response is indispensable for the rational development of effective antimalarial vaccines and novel therapies to alleviate or prevent the parasitemia and increased survival (2.2) due to high levels of IFN-γ and TNF-α in the early stage. However, this immune response increased mortality during the chronic stage of malaria (2.3) and increased severe pathology, such as ECM and severe malaria anemia (SMA) (2.4). In contrast, chronically helminth-infected mice (3) increased the transmission of Plasmodium (3.1), parasitemia and mortality (3.2) due to high levels of IL-4, IL-10, and TGFB and low levels of IFN-γ and TNF-α. However, during the course of the coinfection, the Th1 response against Plasmodium was increased. In fact, a mixed Th1/Th2 response during the chronic stage induced low levels of parasitemia and was asymptomatic (3.3). Interestingly, chronic helminth infections inhibited severe pathologies caused by Plasmodium, such as ECM and SMA (3.4), and increased the survival due to a decreased inflammatory response. Abbreviations: Schistosoma mansoni (Sm), Heligmosomoides polygyrus (Hp), Echinostoma caproni (Ec), Strongyloides ratti (Sr), Nippostrongylus brasiliensis (Nb), Litomosoides sigmodontis (Ls), Brugia pahangi (Bp), and Trichinella spiralis (Ts).

**Conflict of Interests**

The authors have no financial or other conflicts to declare.

**Acknowledgments**

The authors thank Dr. Pascal Hérion for critical review of the paper. They also thank CONACYT-México no. 0443480 for supported Ph.D. fellowship for the first author, Víctor H. Salazar-Castañón, to obtain his degree in biomedical sciences, UNAM. This work was supported by Grants 152224 from CONACYT and IN212412 from UNAM-DGAPA-PAPIIT.
References

[1] P. J. Hotez, P. J. Brindley, J. M. Bethony, C. H. King, E. J. Pearce, and I. Jacobson, “Helminth infections: the great neglected tropical diseases,” The Journal of Clinical Investigation, vol. 118, no. 4, pp. 1311–1321, 2008.

[2] S. L. Hay, E. A. Okiro, P. W. Gething et al., “Estimating the global clinical burden of Plasmodium falciparum malaria in 2007,” PLoS Medicine, vol. 7, no. 6, Article ID e1000290, 2010.

[3] L. E. G. Mboera, K. P. Senkoro, S. F. Rumisha, B. K. Mayala, E. H. Shayo, and M. R. S. Mlozi, “Plasmodium falciparum and helminth coinfections among schoolchildren in relation to agro-ecosystems in Mvomero District, Tanzania,” Acta Tropica, vol. 120, no. 1-2, pp. 95–102, 2011.

[4] S. Brooker, W. Akhwale, R. Pullan et al., “Epidemiology of Plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining control,” American Journal of Tropical Medicine and Hygiene, vol. 77, no. 6, pp. 88–98, 2007.

[5] S. Telfer, R. Birtles, M. Bennett, X. Lambin, S. Paterson, and M. Begon, “Parasite interactions in natural populations: insights from longitudinal data,” Parasitology, vol. 135, no. 7, pp. 767–781, 2008.

[6] S. Telfer, X. Lambin, R. Birtles et al., “Species interactions in a parasite community drive infection risk in a wildlife population,” Science, vol. 330, no. 6001, pp. 243–246, 2010.

[7] A. J. Marshall, L. R. Brunet, Y. Van Gessel et al., “Toxoplasma gondii and Schistosoma mansoni synergize to promote hepatocyte dysfunction associated with high levels of plasma TNF-α and early death in C57Bl/6 mice,” Journal of Immunology, vol. 163, no. 4, pp. 2089–2097, 1999.

[8] M. Rodriguez, L. I. Terrazas, R. Márquez, and R. Bojalil, “Susceptibility to Trypanosoma cruzi is modified by a previous non-related infection,” Parasite Immunology, vol. 21, no. 4, pp. 177–185, 1999.

[9] M. Rodriguez-Sosa, I. Rivera-Montoya, A. Espinoza et al., “Acute cystercerosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages,” Cellular Immunology, vol. 242, no. 2, pp. 61–71, 2006.

[10] C. E. Matisz, J. J. McDougall, K. A. Sharkey, and D. M. McKay, “Helminth parasites and the modulation of joint inflammation,” Journal of Parasitology Research, vol. 2011, Article ID 942616, 8 pages, 2011.

[11] S. Jeremiah, A. B. Janagond, and S. C. Parija, “Challenges in diagnosis of Plasmodium knowlesi infections,” Tropical Parasitology, vol. 4, no. 1, pp. 25–30, 2010.

[12] M. M. Stevenson and E. M. Riley, “Innate immunity to malaria,” Nature Reviews Immunology, vol. 4, no. 3, pp. 169–180, 2004.

[13] M. F. Good, H. Xu, M. Wykes, and C. R. Engwerda, “Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research,” Annual Review of Immunology, vol. 23, pp. 69–99, 2005.

[14] M. Hernandez-Valladares, J. Naessens, and F. A. Iraqi, “Genetic resistance to malaria in mouse models,” Trends in Parasitology, vol. 21, no. 8, pp. 352–355, 2005.

[15] M. Asami, M. Ohashi, T. Abe, and Y. Nawa, “A comparative study of the kinetic changes of hematopoietic stem cells in mice infected with lethal and non-lethal malaria,” International Journal for Parasitology, vol. 22, no. 1, pp. 43–47, 1992.

[16] N. J. White, G. D. H. Turner, I. M. Medana, A. M. Dondorp, and N. P. J. Day, “The murine cerebral malaria phenomenon,” Trends in Parasitology, vol. 26, no. 1, pp. 11–15, 2010.

[17] C. R. Engwerda, L. Beattie, and F. H. Amante, “The importance of the spleen in malaria,” Trends in Parasitology, vol. 21, no. 2, pp. 75–80, 2005.

[18] O. C. Oliveira-Lima, D. Bernardes, M. C. Xavier Pinto, R. M. Esteves Arantes, and I. Carvalho-Tavares, “Mice lacking inducible nitric oxide synthase develop exacerbated hepatic inflammatory responses induced by Plasmodium berghei NK65 infection,” Microbes and Infection, vol. 15, no. 13, pp. 903–910, 2013.

[19] T. Yoshimoto, Y. Takahama, C. Wang, T. Noneto, S. Waki, and H. Naruiuchi, “A pathogenic role of IL-12 in blood-stage murine malaria lethal strain Plasmodium berghei NK65 infection,” Journal of Immunology, vol. 160, no. 11, pp. 5500–5505, 1998.

[20] T. Yoshimoto, T. Noneto, S. Waki, and H. Naruiuchi, “Interleukin-12-dependent mechanisms in the clearance of blood-stage murine malaria parasite Plasmodium berghei XAT, an attenuated variant of P. berghei NK65,” Journal of Infectious Diseases, vol. 177, no. 6, pp. 1674–1681, 1998.

[21] L. Weiss, J. Johnson, and W. Weidanz, “Mechanisms of splenic control of murine malaria: tissue culture studies of the erythropoietic interplay of spleen, bone marrow, and blood in lethal (strain 17KL) Plasmodium yoelii malaria in BALB/c mice,” American Journal of Tropical Medicine and Hygiene, vol. 41, no. 2, pp. 135–143, 1989.

[22] P. R. R. Totino, A. D. Magalhães, L. A. Silva, D. M. Banic, C. T. Daniel-Ribeiro, and M. D. F. Ferreira-da-Cruz, “Apoptosis of non-parasitized red blood cells in malaria: a putative mechanism involved in the pathogenesis of anaemia,” Malaria Journal, vol. 9, no. 1, article 350, 2010.

[23] L. J. Panton, G. Knowles, and D. Walliker, “Studies of antigens in Plasmodium yoelii. I. Antigenic differences between parasite lines detected by crossed immuneelectrophoresis,” Parasitology, vol. 89, no. 1, pp. 17–26, 1984.

[24] W. Jarra and K. N. Brown, “Protective immunity to malaria: studies with cloned lines of rodent malaria in CBA/Ca mice. IV. The specificity of mechanisms resulting in crisis and resolution of the primary acute phase parasitaemia of Plasmodium chabaudi chabaudi and P. yoelii yoelii,” Parasite Immunology, vol. 11, no. 1, pp. 1–13, 1989.

[25] G. S. Yap and M. M. Stevenson, “Plasmodium chabaudi AS: erythropoietic responses during infection in resistant and susceptible mice,” Experimental Parasitology, vol. 75, no. 3, pp. 340–352, 1992.

[26] T. J. Lamb and J. Langhorne, “The severity of malarial anaemia in Plasmodium chabaudi infections of BALB/c mice is determined independently of the number of circulating parasites,” Malaria Journal, vol. 7, article 68, 2008.

[27] A. Fortin, M. M. Stevenson, and P. Gros, “Complex genetic control of susceptibility to malaria in mice,” Genes and Immunity, vol. 3, no. 4, pp. 177–186, 2002.

[28] L. A. Sanni, W. Jarra, C. Li, and I. Langhorne, “Cerebral edema and cerebral hemorrhages in interleukin-10-deficient mice infected with Plasmodium chabaudi,” Infection and Immunity, vol. 72, no. 5, pp. 3054–3058, 2004.

[29] J. L. Villeval, A. Lew, and D. Metcalf, “Changes in hemopoietic and regulator levels in mice during fatal or nonfatal malarial infections. I. Erythropoietic populations,” Infection and Immunity, vol. 59, no. 4, pp. 364–374, 1990.

[30] N. Gadsby, R. Lawrence, and R. Carter, “A study on pathogenicity and mosquito transmission success in the rodent malaria parasite Plasmodium chabaudi adami,” International Journal for Parasitology, vol. 39, no. 3, pp. 347–354, 2009.
[31] A. J. Siddiqui, J. Bhardwaj, and S. K. Puri, “mRNA expression of cytokines and its impact on outcomes after infection with lethal and nonlethal Plasmodium vinckei parasites,” Parasitology Research, vol. 110, no. 4, pp. 1517–1524, 2012.

[32] B. J. Sina, C. Wright, C. T. Atkinson, R. Ballou, M. Aikawa, and M. Hollingdale, “Characterization of a sporozoite antigen common to Plasmodium falciparum and Plasmodium berghei,” Molecular and Biochemical Parasitology, vol. 69, no. 2, pp. 239–246, 1995.

[33] A. P. Almeida, M. O. Dias, A. A. F. Vieira et al., “Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein,” Vaccine, vol. 32, no. 19, pp. 2181–2187, 2014.

[34] B. Ferraro, K. T. Talbotta, A. Balakrishnana et al., “Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA,” Infection and Immunity, vol. 81, no. 10, pp. 3709–3720, 2013.

[35] J. Langhorne, F. M. Ndungu, A. Sponaas, and K. Marsh, “Immunity to malaria: more questions than answers,” Nature Immunology, vol. 9, no. 7, pp. 723–732, 2008.

[36] T. Imai, J. Shen, B. Chou et al., “Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain,” European Journal of Immunology, vol. 40, no. 4, pp. 1053–1061, 2010.

[37] K. Mohan, P. Moulin, and M. M. Stevenson, “Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection,” Journal of Immunology, vol. 159, no. 10, pp. 4990–4998, 1997.

[38] H. R. Choudhury, N. A. Sheikh, G. J. Bancroft, D. R. Katz, and J. B. de Souza, “Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria,” Infection and Immunity, vol. 68, no. 11, pp. 6127–6132, 2000.

[39] A. Fortin, M. M. Stevenson, and P. Gros, “Susceptibility to malaria as a complex trait: big pressure from a tiny creature,” Human Molecular Genetics, vol. 11, no. 20, pp. 2469–2478, 2002.

[40] K. N. Couper, D. G. Blount, J. C. R. Haftalla, N. van Rooijen, J. B. de Souza, and E. M. Riley, “Macrophage-mediated but gamma interferon-independent innate immune responses control the primary wave of Plasmodium yoelii parasitemia,” Infection and Immunity, vol. 75, no. 12, pp. 5806–5818, 2007.

[41] I. A. Clark, N. H. Hunt, G. A. Butcher, and W. B. Cowden, “Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-y or tumor necrosis factor, and its enhancement by butylated hydroxyanisole,” The Journal of Experimental Medicine, vol. 159, no. 10, pp. 3493–3496, 1984.

[42] F. Kobayashi, T. Morii, T. Matsui et al., “Production of interleukin 10 during malaria caused by lethal and nonlethal variants of Plasmodium yoelii yoelii,” Parasitology Research, vol. 82, no. 5, pp. 385–391, 1996.

[43] N. H. Hunt and G. E. Grau, “Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria,” Trends in Immunology, vol. 24, no. 9, pp. 491–499, 2003.

[44] M. K. Mannoor, R. C. Halder, S. R. M. Morshed et al., “Essential role of extrathymic T cells in protection against malaria,” Journal of Immunology, vol. 169, no. 1, pp. 301–306, 2002.

[45] Z. Su and M. M. Stevenson, “IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice,” Journal of Immunology, vol. 168, no. 3, pp. 1348–1355, 2002.

[46] M. N. Wykes, X. Q. Liu, L. Beattie et al., “Plasmodium strain determines dendritic cell function essential for survival from malaria,” PLoS Pathogens, vol. 3, no. 7, article e96, 2007.

[47] J. A. Martiney, B. Sherry, C. N. Metz et al., “Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia,” Infection and Immunity, vol. 68, no. 4, pp. 2259–2267, 2000.

[48] M. A. McDevitt, J. Xie, G. Shanmugasundaram et al., “A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia,” Journal of Experimental Medicine, vol. 203, no. 5, pp. 1185–1196, 2006.

[49] T. von der Weid, N. Honarvar, and J. Langhorne, “Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection,” Journal of Immunology, vol. 156, no. 7, pp. 2510–2516, 1996.

[50] J. Langhorne, C. Cross, E. Seixas, C. Li, and T. Von Der Weid, “A role for B cells in the development of T cell helper function in a malaria infection in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 4, pp. 1730–1734, 1998.

[51] M. Moser and K. M. Murphy, “Dendritic cell regulation of TH1/TH2 development,” Nature Immunology, vol. 1, no. 3, pp. 199–205, 2000.

[52] M. Lazarou, J. A. Guevara Patiño, R. M. Jennings et al., “Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin Gl (IgGl) and IgGl antibodies,” Infection and Immunity, vol. 77, no. 12, pp. 5659–5667, 2009.

[53] T. von der Weid and J. Langhorne, “Altered response of CD4+ T cell subsets to Plasmodium chabaudi chabaudi in B cell-deficient mice,” International Immunology, vol. 5, no. 10, pp. 1343–1348, 1993.

[54] A. W. Taylor-Robinson and R. S. Phillips, “Reconstitution of B-cell-depleted mice with B cells restores Th2-type immune responses during Plasmodium chabaudi chabaudi infection,” Infection and Immunity, vol. 64, no. 1, pp. 366–370, 1996.

[55] K. Haldar and N. Mohandas, “Malaria, erythrocytic infection, and anemia,” American Society of Hematology: Education Program, pp. 87–93, 2009.

[56] G. Pasvol, B. Clough, and J. Carlsson, “Malaria and the red cell membrane,” Blood Reviews, vol. 6, no. 4, pp. 183–192, 1992.

[57] P. A. Buffet, I. Safekou, G. Milon, O. Mercereau-Puijalon, and P. H. David, “Retention of erythrocytes in the spleen: a double-edged process in human malaria,” Current Opinion in Hematology, vol. 16, no. 3, pp. 157–164, 2009.

[58] C. V. Nweneka, C. P. Doherty, S. Cox, and A. Prentice, “Iron delocalisation in the pathogenesis of malarial anemia,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 104, no. 3, pp. 175–184, 2010.

[59] R. S. Barsoum, “Malarial nephropathies,” Nephrology Dialysis Transplantation, vol. 13, no. 6, pp. 1588–1597, 1998.

[60] J. H. H. Ehrich and F. U. Eke, “Malaria-induced renal damage: facts and myths,” Pediatric Nephrology, vol. 22, no. 5, pp. 626–637, 2007.

[61] M. Troye-Blomberg and K. Berzins, “Immune interactions in malaria co-infections with other endemic infectious diseases: implications for the development of improved disease interventions,” Microbes and Infection, vol. 10, no. 9, pp. 948–952, 2008.
[93] L. Hussaarts, L. E. P. M. van der Vlugt, M. Yazdanbakhsh, and H. H. Smits, "Regulatory B-cell induction by helminths: implications for allergic disease," *Journal of Allergy and Clinical Immunology*, vol. 128, no. 4, pp. 733–739, 2011.

[94] O. Atochina, T. Daly-Engel, D. Piskorska, E. McGuire, and D. A. Harn, "A schistosome-expressed immunomodulatory glyco-conjugate expands peritoneal Gr1+ macrophages that suppress naive CD4+ T cell proliferation via an IFN-γ and nitric oxide-dependent mechanism," *Journal of Immunology*, vol. 167, no. 8, pp. 4293–4302, 2001.

[95] S. J. Jenkins and J. E. Allen, "Similarity and diversity in macrophage activation by nematodes, trematodes, and cestodes," *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 262609, 14 pages, 2010.

[96] B. Everts, H. H. Smits, C. H. Hokke, and M. Yazdanbakhsh, "Helminths and dendritic cells: sensing and regulating via pattern recognition receptors, Th2 and Treg responses," *European Journal of Immunology*, vol. 40, no. 6, pp. 1525–1537, 2010.

[97] C. A. Terrazas, L. Gómez-García, and L. I. Terrazas, "Impaired pro-inflammatory cytokine production and increased Th2-biasing ability of dendritic cells exposed to Taenia excreted/secreted antigens: a critical role for carbohydrates but not for STAT6 signaling," *International Journal for Parasitology*, vol. 40, no. 9, pp. 1051–1062, 2010.

[98] A. C. La Flamme, P. Scott, and E. J. Pearce, "Schistosomiasis delays lesion resolution during *Leishmania major* infection by impairing parasite killing by macrophages," *Parasite Immunology*, vol. 24, no. 7, pp. 339–345, 2002.

[99] P. J. Cooper, I. Espinel, W. Paredes, R. H. Guderian, and T. B. Nutman, "Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10," *Journal of Infectious Diseases*, vol. 178, no. 4, pp. 1133–1138, 1998.

[100] D. Elias, H. Akuffo, A. Pawlowski, M. Haile, T. Schöhn, and S. Britton, "*Schistosoma mansoni* infection reduces the protective efficacy of BCG vaccination against virulent *Mycobacterium tuberculosis*," *Vaccine*, vol. 23, no. 11, pp. 1326–1334, 2005.

[101] H. D. Kilian and G. Nielsen, "Cell-mediated and humoral immune responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients," *Tropical Medicine and Parasitology*, vol. 40, no. 4, pp. 445–453, 1989.

[102] P. J. Cooper, M. Chico, C. Sandoval et al., "Human infection with *Ascaris lumbricoides* is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR," *Infection and Immunology*, vol. 69, no. 3, pp. 1574–1580, 2001.

[103] R. W. Summers, D. E. Elliot, J. F. Urban Jr., R. Thompson, and J. V. Weinstock, "*Trichuris suis* therapy in Crohn’s disease," *Gut*, vol. 54, no. 1, pp. 87–90, 2005.

[104] R. W. Summers, D. E. Elliot, J. F. Urban Jr., R. A. Thompson, and J. V. Weinstock, "*Trichuris suis* therapy for active ulcerative colitis: a randomized controlled trial," *Gastroenterology*, vol. 128, no. 4, pp. 825–832, 2005.

[105] H. H. Smits and M. Yazdanbakhsh, "Chronic helminth infections modulate allergen-specific immune responses: protection against development of allergic disorders?" *Annals of Medicine*, vol. 39, no. 6, pp. 428–439, 2007.

[106] H. H. Smits, H. Hammad, M. van Nimwegen et al., "Protective effect of *Schistosoma mansoni* infection on allergic airway inflammation depends on the intensity and chronicity of infection," *Journal of Allergy and Clinical Immunology*, vol. 120, no. 4, pp. 932–940, 2007.

[107] M. S. Wilson and R. M. Maizels, "Regulation of allergy and autoimmunity in helminth infection," *Clinical Reviews in Allergy and Immunology*, vol. 26, no. 1, pp. 35–50, 2004.

[108] J. L. Reyes, A. F. Espinoza-Jiménez, M. I. González, L. Verdin, and L. I. Terrazas, "*Taenia crassiceps* infection abrogates experimental autoimmune encephalomyelitis," *Cellular Immunology*, vol. 267, no. 2, pp. 77–87, 2011.

[109] A. Gruden-Movsesijan, N. Ilic, M. Mostarica-Stojkovic, S. Stosic-Grujicic, M. Milic, and L. Sofronic-Milosavljevic, "*Trichinella spiralis* modulation of experimental autoimmune encephalomyelitis in DA rats," *Experimental Parasitology*, vol. 118, no. 4, pp. 641–647, 2008.

[110] F. A. C. Rocha, A. K. R. M. Leite, M. M. L. Pompeu et al., "Protective effect of an extract from *Ascaris suum* in experimental arthritis models," *Infection and Immunity*, vol. 76, no. 6, pp. 2736–2745, 2008.

[111] S. I. Hay, C. A. Guerra, P. W. Gething et al., "A world malaria map: *Plasmodium falciparum* endemicity in 2007," *PLoS Medicine*, vol. 6, no. 3, Article ID e1000048, 2007.

[112] M. Lemaître, L. Watier, B. Briand, A. García, J. Y. Le Hesran, and M. Cot, "Coinfection with *Plasmodium falciparum* and *Schistosoma haematobium*: additional evidence of the protective effect of Schistosomiasis in Senegalese children," *The American Journal of Tropical Medicine and Hygiene*, vol. 90, no. 2, pp. 329–334, 2014.

[113] H. Dolo, Y. I. Coulibaly, B. Dembele et al., "Filariares attenuates anemia and proinflammatory responses associated with clinical malaria: a matched prospective study in children and young adults," *PLoS Neglected Tropical Diseases*, vol. 6, no. 11, Article ID e1890, 2012.

[114] A. Degarege, M. Lgesse, G. Medhin, A. Animut, and B. Erko, "Malaria and related outcomes in patients with intestinal helminths: a cross-sectional study," *BMCl Infectious Diseases*, vol. 12, article 291, 2012.

[115] A. A. Righetti, D. Glinz, L. G. Adiossan et al., "Interactions and potential implications of *Plasmodium falciparum*-hookworm coinfection in different age groups in South-central Cote d’Ivoire," *PLoS Neglected Tropical Diseases*, vol. 6, no. 11, Article ID e1889, 2012.

[116] G. C. Melo, R. C. Reyes-Lecca, S. Vitor-Silva et al., "Concurrent helminthic infection protects schoolchildren with *Plasmodium vivax* from anemia," *PLoS ONE*, vol. 5, no. 6, Article ID e12106, 2010.

[117] M. Nacher, F. Gay, P. Singhasivanon et al., "*Ascaris lumbricoides* infection is associated with protection from cerebral malaria," *Parasite Immunology*, vol. 22, no. 3, pp. 107–113, 2000.

[118] M. Nacher, P. Singhasivanon, U. Silachamroon et al., "Helminth infections are associated with protection from malaria-related acute renal failure and jaundice in Thailand," *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 6, pp. 834–836, 2001.

[119] L. S. Florey, C. H. King, M. K. van Dyke et al., "Partnering parasites: evidence of synergism between heavy *Schistosoma haematobium* and *plasmodium* species infections in Kenyan children," *PLoS Neglected Tropical Diseases*, vol. 6, no. 7, Article ID e1723, 2012.

[120] F. A. Abanyie, C. McCracken, P. Kirwan et al., "*Ascaris* coinfection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children," *Malaria Journal*, vol. 12, no. 1, article 1, 2013.
[121] A. E. Shapiro, E. M. Tukahebwa, J. Kasten et al., “Epidemiology of helminth infections and their relationship to clinical malaria in southwest Uganda,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 99, no. 1, pp. 18–24, 2005.

[122] M. Nacher, P. Singhhasivanon, S. Yimsamran et al., “Intestinal helminth infections are associated with increased incidence of Plasmodium falciparum malaria in Thailand,” Journal of Parasitology, vol. 88, no. 1, pp. 55–58, 2002.

[123] J. le Hesran, J. Akiana, E. H. M. Ndiaye, M. Dia, P. Senghor, and L. Konate, “Severe malaria attack is associate with high prevalence of Ascaris lumbricoides infection among children in rural Senegal,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 98, no. 7, pp. 397–399, 2004.

[124] C. Sokhna, J. Le Hesran, P. A. Mbaye et al., “Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal,” Malaria Journal, vol. 3, article 43, 2004.

[125] N. J. Yatich, P. E. Jolly, E. Funkhouser et al., “The effect of malaria and intestinal helminth coinfection on birth outcomes in Kumasi, Ghana,” American Journal of Tropical Medicine and Hygiene, vol. 82, no. 1, pp. 28–34, 2010.

[126] A. Degarege, A. Animut, M. Legesse, and B. Erko, “Malaria and helminth co-infections in outpatients of Alaba Kuito Health Center, southern Ethiopia: a cross sectional study,” BMC Research Notes, vol. 3, article 143, 2010.

[127] S. Wilson, F. M. Jones, J. K. Mwatha et al., “Hepatosplenomegaly associated with chronic malaria exposure: evidence for a pro-inflammatory mechanism exacerbated by schistosomiasis,” Parasite Immunology, vol. 31, no. 2, pp. 64–71, 2009.

[128] S. Wilson, F. M. Jones, J. K. Mwatha et al., “Hepatosplenomegaly is associated with low regulatory and Th2 responses to schistosome antigens in childhood schistosomiasis and malaria coinfection,” Infection and Immunity, vol. 76, no. 5, pp. 2212–2218, 2008.

[129] D. T. Sangweme, N. Midzi, S. Zinyowera-Mutapuri, T. Mdu-luza, M. Dienier-West, and N. Kumar, “Impact of schistosome infection on Plasmodium falciparum Malarialometric indices and immune correlates in school age children in Burua valley, Zimbabwe,” PLoS Neglected Tropical Diseases, vol. 4, no. 11, article e882, 2010.

[130] T. K. Nkuo-Akenji, P. C. Chi, J. F. Cho, K. K. J. Ndumukong, and I. Sumbele, “Malaria and helminth co-infection in children living in a malaria endemic setting of Mount Cameroon and predictors of anemia,” Journal of Parasitology, vol. 92, no. 6, pp. 1191–1195, 2006.

[131] N. Ishikawa, P. K. Goyal, Y. R. Mahida, K. Li, and D. Wakelin, “Early cytokine responses during intestinal parasitic infections,” Immunology, vol. 93, no. 2, pp. 257–263, 1998.

[132] G. L. Stewart, H. Na, L. Smart, and L. L. Seelig Jr., “The temporal relationship among anti-parasite immune elements expressed during the early phase of infection of the rat with Trichinella spiralis,” Parasitology Research, vol. 85, no. 8-9, pp. 672–677, 1999.

[133] L. I. Terrazas, R. Bojalil, T. Govezensky, and C. Larralde, “Shift from an early protective Th1-type immune response to a late permissible Th2-type response in murine cestocercosis (Taenia crassiceps),” The Journal of Parasitology, vol. 84, no. 1, pp. 74–81, 1998.

[134] E. J. Pearce and A. S. MacDonald, “The immunobiology of schistosomiasis,” Nature Reviews Immunology, vol. 2, no. 7, pp. 499–511, 2002.

[135] M. L. Eschbach, U. Klemm, J. Kolbaum, B. Blankenhans, N. Brattig, and M. Breloer, “Strongyloides ratti infection induces transient nematode-specific Th2 response and reciprocal suppression of IFN-γ production in mice,” Parasite Immunology, vol. 32, no. 5, pp. 370–383, 2010.

[136] J. H. Waksine-Grinberg, D. Gold, A. Ohayon et al., “Schis- tosoma mansoni infection reduces the incidence of murine cerebral malaria,” Malaria Journal, vol. 9, no. 1, article 5, 2010.

[137] M. L. Wang, Y. M. Cao, E. J. Luo, Y. Zhang, and Y. J. Guo, “Pre-existing Schistosoma japonicum infection alters the immune response to Plasmodium berghei infection in C57BL/6 mice,” Malaria Journal, vol. 12, article 322, 2013.

[138] K. Bucher, K. Dietz, P. Lackner et al., “Schistosoma co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria,” International Journal for Parasitology, vol. 41, no. 1, pp. 21–31, 2011.

[139] M. Legesse, B. Erko, and F. Balcha, “Increased parasitaemia and delayed parasite clearance in Schistosoma mansoni and Plasmodium berghei co-infected mice,” Acta Tropica, vol. 91, no. 2, pp. 161–166, 2004.

[140] H. Helmy, M. Kullberg, and M. Troye-Blomberg, “Altered immune responses in mice with concomitant Schistosoma mansoni and Plasmodium chabaudi infections,” Infection and Immunity, vol. 66, no. 11, pp. 5167–5174, 1998.

[141] D. Sangweme, C. Shiff, and N. Kumar, “Plasmodium yoelii: adverse outcome of non-lethal P. yoelii malaria during co-infection with Schistosoma mansoni in BALB/c mouse model,” Experimental Parasitology, vol. 122, no. 3, pp. 254–259, 2009.

[142] A. Yoshida, H. Maruyama, T. Kumagai et al., “Schistosoma mansoni infection cancels the susceptibility to Plasmodium chabaudi through induction of type 1 immune responses in A/J mice,” International Immunology, vol. 12, no. 8, pp. 1117–1125, 2000.

[143] Z. Su, M. Segura, K. Morgan, J. C. Loredo-Osti, and M. M. Stevenson, “Impairment of protective immunity to blood-stage malaria by concurrent nematode infection,” Infection and Immunity, vol. 73, no. 6, pp. 3531–3539, 2005.

[144] M. Segura, C. Matte, N. Thawani, Z. Su, and M. M. Stevenson, “Modulation of malaria-induced immunopathology by concurrent gastrointestinal nematode infection in mice,” International Journal for Parasitology, vol. 39, no. 14, pp. 1525–1532, 2009.

[145] H. Helmy, “Gastrointestinal nematode infection exacerbates malaria-induced liver pathology,” Journal of Immunology, vol. 182, no. 9, pp. 5663–5671, 2009.

[146] Z. Su, M. Segura, and M. M. Stevenson, “Reduced protective efficacy of a blood-stage malaria vaccine by concurrent nema- tode infection,” Infection and Immunity, vol. 74, no. 4, pp. 2138–2144, 2006.

[147] K. Tetsutani, K. Ishiwata, H. Ishida et al., “Concurrent infection with Heligmosomoides polygyrus suppresses anti-Plasmodium yoelii protection partially by induction of CD4+CD25+Foxp3+ Treg in mice,” European Journal of Immunology, vol. 39, no. 10, pp. 2822–2830, 2009.

[148] G. S. Noland, J. F. Urban Jr., B. Fried, and N. Kumar, “Counter-regulatory anti-parasite cytokine responses during concurrent Plasmodium yoelii and intestinal helminth infections in mice,” Experimental Parasitology, vol. 119, no. 2, pp. 272–278, 2008.

[149] K. Tetsutani, K. Ishiwata, M. Torii, S. Hamano, H. Hisaeda, and K. Himeno, “Short report: concurrent infection with Heligmo- somoides polygyrus modulates murine host response against Plasmodium berghei ANKA infection,” The American Journal of Tropical Medicine and Hygiene, vol. 79, no. 6, pp. 819–822, 2008.
[150] B. de Souza and H. Helmy, "Concurrent gastro-intestinal nematode infection does not alter the development of experimental cerebral malaria," *Microbes and Infection*, vol. 10, no. 8, pp. 916–921, 2008.

[151] G. S. Noland, T. K. Graczyk, B. Fried, E. J. Fitzgerald, and N. Kumar, "Exacerbation of *Plasmodium yoelii* malaria in *Echinostoma caproni* infected mice and abatement through anthelminthic treatment," *Journal of Parasitology*, vol. 91, no. 4, pp. 944–948, 2005.

[152] J. Kolbaum, M.-L. Eschbach, C. Steeg, T. Jacobs, B. Fleischer, and M. Breloer, "Efficient control of *Plasmodium yoelii* infection in BALB/c and C57BL/6 mice with pre-existing *Strongyloides ratti* infection," *Parasite Immunology*, vol. 34, no. 7, pp. 388–393, 2012.

[153] J. Kolbaum, S. Tartz, W. Hartmann et al., "Nematode-induced interference with the anti-*Plasmodium* CD8+ T-cell response can be overcome by optimizing antigen administration," *European Journal of Immunology*, vol. 42, no. 4, pp. 890–900, 2012.

[154] M. A. Hoeve, K. J. Mylonas, K. J. Fairlie-Clarke, S. M. Mahajan, J. E. Allen, and A. L. Graham, "*Plasmodium chabaudi* limits early *Nippostrongylus brasiliensis*-induced pulmonary immune activation and Th2 polarization in co-infected mice," *BMC Immunology*, vol. 10, article 60, 2009.

[155] N. Xiao, T. Furuta, T. Kiguchi, and S. Kojima, "Effect of *Nippostrongylus brasiliensis* induced alterations in T helper cell subsets on *Plasmodium berghei* infection in mice," *Chinese Journal of Parasitology & Parasitic Diseases*, vol. 18, no. 5, pp. 286–290, 2000.

[156] A. L. Graham, T. J. Lamb, A. F. Read, and J. E. Allen, "Malaria-filaria coinfection in mice makes malarial disease more severe unless filarial infection achieves patency," *Journal of Infectious Diseases*, vol. 191, no. 3, pp. 410–421, 2005.

[157] S. Specht, D. F. Ruiz, B. Dubben, S. Deininger, and A. Hoerauf, "Filaria-induced IL-10 suppresses murine cerebral malaria," *Microbes and Infection*, vol. 12, no. 8-9, pp. 635–642, 2010.

[158] Y. Yan, G. Inuo, N. Akao, S. Tsukidate, and K. Fujita, "Down-regulation of murine susceptibility to cerebral malaria by inoculation with third-stage larvae of the filarial nematode *Brugia pahangi*," *Parasitology*, vol. 114, no. 4, pp. 333–338, 1997.

[159] B. Z. Ngwenya, "Enhanced resistance to *Plasmodium berghei* in mice previously infected with *Trichinella spiralis*," *Parasite Immunology*, vol. 4, no. 3, pp. 197–267, 1982.

[160] C. Engwerda, E. Belnoue, A. C. Grüner, and L. Rénia, "Experimental models of cerebral malaria," *Current Topics in Microbiology and Immunology*, vol. 297, pp. 103–143, 2005.

[161] C. Hermesen, T. Van De Wiel, E. Mommers, R. Sauerwein, and W. Eling, "Depletion of CD4+ or CD8+ T-cells prevents *Plasmodium berghei* induced cerebral malaria in end-stage disease," *Parasitology*, vol. 114, no. 1, pp. 7–12, 1997.

[162] B. Min, M. Prout, J. Hu-Li et al., "Basophils produce IL-4 and accumulate in tissues after infection with a Th2-inducing parasite," *Journal of Experimental Medicine*, vol. 200, no. 4, pp. 507–517, 2004.

[163] C. L. L. Chua, G. Brown, J. A. Hamilton, S. Rogerson, and P. Boeuf, "Monocytes and macrophages in malaria: protection or pathology?" *Trends in Parasitology*, vol. 29, no. 1, pp. 26–34, 2013.